Exploring the N-Terminal Region of C-X-C Motif Chemokine 12 (CXCL12): Identification of Plasma-Stable Cyclic Peptides As Novel, Potent C-X-C Chemokine Receptor Type 4 (CXCR4) Antagonists

Salvatore Di Maro, Anna Maria Trotta, Diego Brancaccio, Francesco Saverio Di Leva, Valeria La Pietra, Caterina Ieranò, Maria Napolitano, Luigi Portella, Crescenzo D'Alterio, Rosa Anna Siciliano, Deborah Sementa, Stefano Tomassi, Alfonso Carotenuto, Ettore Novellino, Stefania Scala, Luciana Marinelli

Research output: Contribution to journalArticle

Abstract

We previously reported the discovery of a CXCL12-mimetic cyclic peptide (2) as a selective CXCR4 antagonist showing promising in vitro and in vivo anticancer activity. However, further development of this peptide was hampered by its degradation in biological fluids as well as by its low micromolar affinity for the receptor. Herein, extensive chemical modifications led to the development of a new analogue (10) with enhanced potency, specificity, and plasma stability. A combined approach of Ala-amino acid scan, NMR, and molecular modeling unraveled the reasons behind the improved binding properties of 10 vs 2. Biological investigations on leukemia (CEM) and colon (HT29 and HCT116) cancer cell lines showed that 10 is able to impair CXCL12-mediated cell migration, ERK-phosphorylation, and CXCR4 internalization. These outcomes might pave the way for the future preclinical development of 10 in CXCR4 overexpressing leukemia and colon cancer.

Original languageEnglish
Pages (from-to)8369-8380
Number of pages12
JournalJournal of Medicinal Chemistry
Volume59
Issue number18
DOIs
Publication statusPublished - Sep 22 2016

Fingerprint

Chemokine CXCL12
CXC Chemokines
Cyclic Peptides
Chemokine Receptors
Leukemia
HCT116 Cells
Colonic Neoplasms
Cell Movement
Colon
Phosphorylation
Amino Acids
Cell Line
Peptides
Neoplasms

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery

Cite this

Exploring the N-Terminal Region of C-X-C Motif Chemokine 12 (CXCL12) : Identification of Plasma-Stable Cyclic Peptides As Novel, Potent C-X-C Chemokine Receptor Type 4 (CXCR4) Antagonists. / Di Maro, Salvatore; Trotta, Anna Maria; Brancaccio, Diego; Di Leva, Francesco Saverio; La Pietra, Valeria; Ieranò, Caterina; Napolitano, Maria; Portella, Luigi; D'Alterio, Crescenzo; Siciliano, Rosa Anna; Sementa, Deborah; Tomassi, Stefano; Carotenuto, Alfonso; Novellino, Ettore; Scala, Stefania; Marinelli, Luciana.

In: Journal of Medicinal Chemistry, Vol. 59, No. 18, 22.09.2016, p. 8369-8380.

Research output: Contribution to journalArticle

Di Maro, S, Trotta, AM, Brancaccio, D, Di Leva, FS, La Pietra, V, Ieranò, C, Napolitano, M, Portella, L, D'Alterio, C, Siciliano, RA, Sementa, D, Tomassi, S, Carotenuto, A, Novellino, E, Scala, S & Marinelli, L 2016, 'Exploring the N-Terminal Region of C-X-C Motif Chemokine 12 (CXCL12): Identification of Plasma-Stable Cyclic Peptides As Novel, Potent C-X-C Chemokine Receptor Type 4 (CXCR4) Antagonists', Journal of Medicinal Chemistry, vol. 59, no. 18, pp. 8369-8380. https://doi.org/10.1021/acs.jmedchem.6b00695
Di Maro, Salvatore ; Trotta, Anna Maria ; Brancaccio, Diego ; Di Leva, Francesco Saverio ; La Pietra, Valeria ; Ieranò, Caterina ; Napolitano, Maria ; Portella, Luigi ; D'Alterio, Crescenzo ; Siciliano, Rosa Anna ; Sementa, Deborah ; Tomassi, Stefano ; Carotenuto, Alfonso ; Novellino, Ettore ; Scala, Stefania ; Marinelli, Luciana. / Exploring the N-Terminal Region of C-X-C Motif Chemokine 12 (CXCL12) : Identification of Plasma-Stable Cyclic Peptides As Novel, Potent C-X-C Chemokine Receptor Type 4 (CXCR4) Antagonists. In: Journal of Medicinal Chemistry. 2016 ; Vol. 59, No. 18. pp. 8369-8380.
@article{45d1454987784d598e99a16002b02ad6,
title = "Exploring the N-Terminal Region of C-X-C Motif Chemokine 12 (CXCL12): Identification of Plasma-Stable Cyclic Peptides As Novel, Potent C-X-C Chemokine Receptor Type 4 (CXCR4) Antagonists",
abstract = "We previously reported the discovery of a CXCL12-mimetic cyclic peptide (2) as a selective CXCR4 antagonist showing promising in vitro and in vivo anticancer activity. However, further development of this peptide was hampered by its degradation in biological fluids as well as by its low micromolar affinity for the receptor. Herein, extensive chemical modifications led to the development of a new analogue (10) with enhanced potency, specificity, and plasma stability. A combined approach of Ala-amino acid scan, NMR, and molecular modeling unraveled the reasons behind the improved binding properties of 10 vs 2. Biological investigations on leukemia (CEM) and colon (HT29 and HCT116) cancer cell lines showed that 10 is able to impair CXCL12-mediated cell migration, ERK-phosphorylation, and CXCR4 internalization. These outcomes might pave the way for the future preclinical development of 10 in CXCR4 overexpressing leukemia and colon cancer.",
author = "{Di Maro}, Salvatore and Trotta, {Anna Maria} and Diego Brancaccio and {Di Leva}, {Francesco Saverio} and {La Pietra}, Valeria and Caterina Ieran{\`o} and Maria Napolitano and Luigi Portella and Crescenzo D'Alterio and Siciliano, {Rosa Anna} and Deborah Sementa and Stefano Tomassi and Alfonso Carotenuto and Ettore Novellino and Stefania Scala and Luciana Marinelli",
year = "2016",
month = "9",
day = "22",
doi = "10.1021/acs.jmedchem.6b00695",
language = "English",
volume = "59",
pages = "8369--8380",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "American Chemical Society",
number = "18",

}

TY - JOUR

T1 - Exploring the N-Terminal Region of C-X-C Motif Chemokine 12 (CXCL12)

T2 - Identification of Plasma-Stable Cyclic Peptides As Novel, Potent C-X-C Chemokine Receptor Type 4 (CXCR4) Antagonists

AU - Di Maro, Salvatore

AU - Trotta, Anna Maria

AU - Brancaccio, Diego

AU - Di Leva, Francesco Saverio

AU - La Pietra, Valeria

AU - Ieranò, Caterina

AU - Napolitano, Maria

AU - Portella, Luigi

AU - D'Alterio, Crescenzo

AU - Siciliano, Rosa Anna

AU - Sementa, Deborah

AU - Tomassi, Stefano

AU - Carotenuto, Alfonso

AU - Novellino, Ettore

AU - Scala, Stefania

AU - Marinelli, Luciana

PY - 2016/9/22

Y1 - 2016/9/22

N2 - We previously reported the discovery of a CXCL12-mimetic cyclic peptide (2) as a selective CXCR4 antagonist showing promising in vitro and in vivo anticancer activity. However, further development of this peptide was hampered by its degradation in biological fluids as well as by its low micromolar affinity for the receptor. Herein, extensive chemical modifications led to the development of a new analogue (10) with enhanced potency, specificity, and plasma stability. A combined approach of Ala-amino acid scan, NMR, and molecular modeling unraveled the reasons behind the improved binding properties of 10 vs 2. Biological investigations on leukemia (CEM) and colon (HT29 and HCT116) cancer cell lines showed that 10 is able to impair CXCL12-mediated cell migration, ERK-phosphorylation, and CXCR4 internalization. These outcomes might pave the way for the future preclinical development of 10 in CXCR4 overexpressing leukemia and colon cancer.

AB - We previously reported the discovery of a CXCL12-mimetic cyclic peptide (2) as a selective CXCR4 antagonist showing promising in vitro and in vivo anticancer activity. However, further development of this peptide was hampered by its degradation in biological fluids as well as by its low micromolar affinity for the receptor. Herein, extensive chemical modifications led to the development of a new analogue (10) with enhanced potency, specificity, and plasma stability. A combined approach of Ala-amino acid scan, NMR, and molecular modeling unraveled the reasons behind the improved binding properties of 10 vs 2. Biological investigations on leukemia (CEM) and colon (HT29 and HCT116) cancer cell lines showed that 10 is able to impair CXCL12-mediated cell migration, ERK-phosphorylation, and CXCR4 internalization. These outcomes might pave the way for the future preclinical development of 10 in CXCR4 overexpressing leukemia and colon cancer.

UR - http://www.scopus.com/inward/record.url?scp=84988733628&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84988733628&partnerID=8YFLogxK

U2 - 10.1021/acs.jmedchem.6b00695

DO - 10.1021/acs.jmedchem.6b00695

M3 - Article

AN - SCOPUS:84988733628

VL - 59

SP - 8369

EP - 8380

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 18

ER -